share_log

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

Benzinga Real-time News ·  Nov 15, 2022 07:06

Chardan Capital analyst Keay Nakae maintains Better Therapeutics (NASDAQ:BTTX) with a Buy and lowers the price target from $17 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment